Medicare Enrolled
Dr. Lynn Kong, MD
Hematology & Oncology · Ventura, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kong from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kong?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kong
Dr. Lynn Kong is a hematology & oncology specialist in Ventura, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Kong performed 6,594 Medicare services across 2,447 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kong received a total of $15,312 from 80 pharmaceutical and/or device companies across 710 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kong is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 31% volume in CA
$15,312 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,594
Medicare services
Top 31% in CA for hematology & oncology
2,447
Unique beneficiaries
$40
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~347 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,112 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,954 | $8 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,171 | $98 | $195 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
694 | $68 | $150 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
224 | $72 | $100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
127 | $141 | $250 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
100 | $98 | $205 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
77 | $64 | $185 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
58 | $143 | $395 |
| New patient office visit, complex (60-74 min) | 30 | $186 | $375 |
| Principal care management for high-risk disease, first 30 minutes This service involves 30 minutes of personal care management by a qualified healthcare professional for a patient with a single high-risk disease, billed per calendar month. |
26 | $63 | $100 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
21 | $135 | $295 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$15,312
Total received (2018-2024)
Avg $2,187/year across 7 years
Top 26% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
80
Companies
710
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,465 (94.5%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$514 (3.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$333 (2.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,922
2023
$3,364
2022
$2,474
2021
$744
2020
$577
2019
$2,103
2018
$2,128
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$353
PFIZER INC.
$329
EMD Serono, Inc.
$299
Novartis Pharmaceuticals Corporation
$274
ABBVIE INC.
$274
Merck Sharp & Dohme LLC
$243
Incyte Corporation
$202
Gilead Sciences, Inc.
$173
Celgene Corporation
$143
Astellas Pharma US Inc
$121
Daiichi Sankyo Inc.
$115
Janssen Biotech, Inc.
$107
Karyopharm Therapeutics Inc.
$95
E.R. Squibb & Sons, L.L.C.
$87
Genentech USA, Inc.
$80
Eisai Inc.
$73
Exelixis Inc.
$72
Blueprint Medicines Corporation
$71
SUN PHARMACEUTICAL INDUSTRIES INC.
$66
Mirati Therapeutics, Inc.
$63
GlaxoSmithKline, LLC.
$60
Genmab U.S., Inc.
$56
Agios Pharmaceuticals, Inc.
$41
Lilly USA, LLC
$38
Aveo Pharmaceuticals, Inc.
$37
Regeneron Healthcare Solutions, Inc.
$36
Coherus Biosciences Inc.
$36
ARRAY BIOPHARMA INC
$33
PharmaEssentia USA Corporation
$31
ADC Therapeutics America, Inc.
$31
Blue Earth Diagnostics Limited
$29
Myriad Genetic Laboratories, Inc.
$27
Tempus AI, Inc
$27
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
Takeda Pharmaceuticals U.S.A., Inc.
$25
Fresenius Kabi USA, LLC
$24
Verity Pharmaceuticals Inc.
$24
Alnylam Pharmaceuticals Inc.
$21
Immunocore Limited
$21
JAZZ PHARMACEUTICALS INC.
$21
Stemline Therapeutics Inc.
$20
Tactile Systems Technology Inc
$18
Top 3 companies account for 25.0% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,563
GlaxoSmithKline, LLC.
$759
PFIZER INC.
$688
Celgene Corporation
$685
Incyte Corporation
$676
Novartis Pharmaceuticals Corporation
$648
Amgen Inc.
$625
E.R. Squibb & Sons, L.L.C.
$599
Merck Sharp & Dohme LLC
$485
EMD Serono, Inc.
$479
Pharmacyclics LLC, An AbbVie Company
$448
ABBVIE INC.
$429
Genentech USA, Inc.
$423
Janssen Biotech, Inc.
$405
Gilead Sciences, Inc.
$339
Exelixis Inc.
$320
Seagen Inc.
$317
Merck Sharp & Dohme Corporation
$299
Eisai Inc.
$290
Astellas Pharma US Inc
$287
Lilly USA, LLC
$277
TESARO, Inc.
$254
Blueprint Medicines Corporation
$250
ADC Therapeutics America, Inc.
$244
Daiichi Sankyo Inc.
$216
Array BioPharma Inc.
$205
Takeda Pharmaceuticals U.S.A., Inc.
$190
Karyopharm Therapeutics Inc.
$185
Alnylam Pharmaceuticals Inc.
$136
Seattle Genetics, Inc.
$131
GENZYME CORPORATION
$125
EISAI INC.
$119
Alexion Pharmaceuticals, Inc.
$114
Regeneron Healthcare Solutions, Inc.
$101
Pharmacyclics LLC, an AbbVie Company
$96
Mirati Therapeutics, Inc.
$91
PharmaEssentia USA Corporation
$89
Foundation Medicine, Inc.
$87
Clovis Oncology, Inc.
$82
MorphoSys, US Inc.
$81
Ipsen Biopharmaceuticals, Inc
$79
Puma Biotechnology, Inc.
$77
Myriad Genetic Laboratories, Inc.
$76
SOBI, INC
$69
Dendreon Pharmaceuticals LLC
$67
BeiGene USA, Inc.
$66
SUN PHARMACEUTICAL INDUSTRIES INC.
$66
Genmab U.S., Inc.
$56
Aveo Pharmaceuticals, Inc.
$55
Tactile Systems Technology Inc
$47
Teva Pharmaceuticals USA, Inc.
$46
Blue Earth Diagnostics Limited
$46
Spectrum Pharmaceuticals Inc.
$44
Lexicon Pharmaceuticals, Inc.
$44
Fresenius Kabi USA, LLC
$43
GE HealthCare
$42
Agios Pharmaceuticals, Inc.
$41
Jazz Pharmaceuticals Inc.
$38
Coherus Biosciences Inc.
$36
ARRAY BIOPHARMA INC
$33
Tempus AI, Inc
$27
Mylan Institutional Inc.
$27
Boehringer Ingelheim Pharmaceuticals, Inc.
$26
Verity Pharmaceuticals Inc.
$24
AbbVie, Inc.
$23
Bayer HealthCare Pharmaceuticals Inc.
$23
RECORDATI_RARE_DISEASES_INC.
$22
Heron Therapeutics, Inc.
$22
TAIHO ONCOLOGY, INC.
$22
Immunocore Limited
$21
JAZZ PHARMACEUTICALS INC.
$21
Stemline Therapeutics Inc.
$20
Acerta Pharma LLC
$19
AVEO Pharmaceuticals, Inc.
$17
Kite Pharma, Inc.
$17
Janssen Pharmaceuticals, Inc
$16
Kyowa Kirin, Inc.
$16
INSYS Therapeutics Inc
$13
MEDIVATION FIELD SOLUTIONS LLC
$13
Sobi, Inc
$12
Top 3 companies account for 19.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · AMVUTTRA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Axumin · BENDEKA · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELITEK · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · EVENITY · Enhertu · Epkinly · Erleada · FASLODEX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · FULPHILA · Fabhalta · Flexitouch Plus · Folotyn · GAZYVA · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OJJAARA · ONPATTRO · OPDIVO · OPDUALAG · PADCEV · PEMAZYRE · PLUVICTO · POSLUMA · PROMACTA · PROVENGE · PYRUKYND · Padcev · Pomalyst · Poteligeo · Prolia · REBLOZYL · RYDAPT · Revlimid · Rubraca · SANDOSTATIN LAR · SARCLISA · SHINGRIX · SOMATULINE DEPOT · SUSTOL · SUTENT · SYLVANT · SYNDROS · Stimufend · TAGRISSO · TALVEY · TALZENNA · TASIGNA · TECENTRIQ · TEPMETKO · TIVDAK · TUKYSA · Tecentriq · Trelstar · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · Venclexta · Vyloy · XALKORI · XPOVIO · XTANDI · Xermelo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (94%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
16
Per 100K population
1.9
County median income
$107,327
Nearest hospital
VENTURA COUNTY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kong is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kong experienced with blood draw (venipuncture)?
Based on Medicare claims data, Dr. Kong performed 2,112 blood draw (venipuncture) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kong receive payments from pharmaceutical companies?
Yes. Dr. Kong received a total of $15,312 from 80 companies across 710 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kong's costs compare to other hematology & oncology specialists in Ventura?
Dr. Kong's average Medicare payment per service is $40. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kong) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Ventura
Browse hematology & oncology specialists in Ventura ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology